New hope for kidney patients: dapagliflozin trial targets slowing disease

NCT ID NCT06610526

Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing the drug dapagliflozin in 731 Chinese adults with chronic kidney disease. The goal is to see if the drug can slow kidney decline and is safe. Participants take the drug by mouth, and researchers track kidney function and side effects over time.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance: Dapagliflozin (a drug taken by mouth that helps protect the kidneys)
What this could lead to: If it works, this could provide a new treatment option to slow kidney disease progression in Chinese patients.
What could go wrong: This is a single-arm, open-label study without a placebo group, so results may be less reliable. It is also limited to Chinese adults, so findings may not apply to other populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

731 people

The number who actually took part.

Started

Aug 2024

Expected to finish

May 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 130 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Provision of signed informed consent prior to any study specific procedures * Chinese Female or male aged ≥ 18 years at the time of consent * eGFR ≥ 25 and ≤ 75 mL/min/1.73m2 (CKD-EPI Formula) at visit 1 * Evidence of increased albuminuria 3 months or more before visit 1 and UACR ≥ 200 and ≤ 5000 mg/g at visit 1 * Stable, and for the patient maximum tolerated labelled daily dose, treatment with ACE-I or ARB for at least 4 weeks before visit 1, if not medically contraindicated Exclusion Criteria: * Autosomal dominant or autosomal recessive polycystic kidney disease, lupus nephritis or anti-neutrophil cytoplasmic antibodies-associated vasculitis * Receiving cytotoxic therapy, immunosuppressive therapy or other immunotherapy for primary or secondary renal disease within 6 months prior to enrolment * History of organ transplantation * Receiving therapy with an SGLT2 inhibitor within 8 weeks prior to enrolment or previous intolerance of an SGLT2 inhibitor * T1DM * New York Heart Association class IV Congestive Heart Failure at the time of enrolment * MI, unstable angina, stroke or TIA within 12 weeks prior to enrolment * Coronary revascularization (PCI or CABG) or valvular repair/replacement within 12 weeks prior to enrolment * Any condition outside the renal and CV disease area, such as but not limited to malignancy, with a life expectancy of less than 2 years based on investigator´s clinical judgement * Active malignancy requiring treatment at the time of visit 1 (with the exception of successfully treated basal cell or treated squamous cell carcinoma) * Hepatic impairment (AST or ALT \> 3 × ULN; or total bilirubin \> 2 × ULN at time of enrolment). An solated increase in bilirubin in patients with known Gilbert's syndrome is not a reason for exclusion * Known blood-borne diseases * Women of child-bearing potential (ie, those who are not chemically or surgically sterilised or who are not post-menopausal) who are not willing to use a medically accepted method of contraception that is considered reliable in the judgment of the investigator, from the time of signing the informed consent throughout the study and 4 weeks thereafter, OR women who have a positive pregnancy test at enrolment OR women who are breast-feeding * Involvement in the planning and/or conduct of the study (applies to both AstraZeneca personnel and/or site personnel) * Previous enrolled in the present study * Participation in another clinical study with a study intervention during the last month prior to enrolment * Inability of the patient, in the opinion of the investigator, to understand and/or comply with study intervention, procedures and/or follow-up OR any conditions that, in the opinion of the investigator, may render the patient unable to complete the study

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic kidney disease chronic renal failure syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic kidney disease

Contacts and locations

Locations

Research Site

Beijing, 100034, China
Research Site

Beijing, 100044, China
Research Site

Beijing, 100068, China
Research Site

Beijing, 100191, China
Research Site

Beijing, 102206, China
Research Site

Changchun, 130021, China
Research Site

Dongguan, 523059, China
Research Site

Foshan, 528308, China
Research Site

Fuyang, 236012, China
Research Site

Fuzhou, 350001, China
Research Site

Ganzhou, 341099, China
Research Site

Harbin, 150000, China
Research Site

Hefei, 230601, China
Research Site

Hengyang, 421001, China
Research Site

Huaian, 223399, China
Research Site

Huizhou, 516001, China
Research Site

Jilin City, 132011, China
Research Site

Jinan, 250014, China
Research Site

Jining, 272029, China
Research Site

Lanzhou, 730000, China
Research Site

Linyi, 276199, China
Research Site

Nanchang, 330006, China
Research Site

Nanjing, 210029, China
Research Site

Nanning, 530021, China
Research Site

Ningbo, 315010, China
Research Site

Shanghai, 200090, China
Research Site

Shenzhen, 518036, China
Research Site

Suzhou, 215004, China
Research Site

Taian, 271099, China
Research Site

Tianjin, 300121, China
Research Site

Wuhu, 241000, China
Research Site

Wuxi, 214023, China
Research Site

Xi'an, 710000, China
Research Site

Xiamen, 361004, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.